Results 211 to 220 of about 9,522 (255)
Some of the next articles are maybe not open access.
Latanoprost in hemifacial spasm
Prostaglandins & Other Lipid Mediators, 2002An empirical observation that the prostaglandin derivate latanoprost quited facial spasms in patients with glaucoma prompted us to study latanoprost in non-glaucomatous patients with hemifacial spasms [HFS]. This explorative trial followed an open-label, prospective treatment design.
Luc Crevits +3 more
openaire +3 more sources
The stabilization mechanism of latanoprost
International Journal of Pharmaceutics, 2011The content of latanoprost is likely to decrease in solution because of the adsorption to eye drop containers and hydrolysis. We reduced these problems and established a formulation of latanoprost eye drops which is stable at room temperature. We assume that the additive surfactants form micelles and stabilize latanoprost in this formulation.
Akiko Ochiai, Kazumi Danjo
openaire +3 more sources
Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Drug Development and Industrial Pharmacy, 2020Objective: Glaucoma is a leading cause of irreversible blindness worldwide. Whereas latanoprost is one of the most effective drugs in glaucoma treatment, its eye drops need frequent application leading to lack of patient adherence.
Dina Fathalla, E. Fouad, G. M. Soliman
semanticscholar +1 more source
Combined Therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy
Survey of Ophthalmology, 2002Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP.
Michael Diestelhorst +2 more
openaire +3 more sources
Synthesis of latanoprost diastereoisomers
Chirality, 2005A new synthesis of latanoprost diastereoisomers is described which utilizes a highly stereoselective Michael addition of higher-order cuprate to a chiral cyclopentenone derived from G-lactone in the crucial skeleton-forming step.
Josef Hajicek +3 more
openaire +3 more sources
Latanoprost, a balanced prostaglandin
Expert Review of Ophthalmology, 2019Introduction: Glaucoma is a leading cause of blindness and represents a significant global health and economic concern. Prostaglandin analogs such as latanoprost – which act to reduce intraocular pressure by enhancing uveoscleral flow and slow the development and progression of glaucoma – are recommended as a first-line monotherapy.Areas covered: We ...
Jose M. Martinez-de-la-Casa +2 more
openaire +2 more sources
An Evaluation of the Rate of Nonresponders to Latanoprost Therapy
Journal of Glaucoma, 2006To determine the proportion of patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who do not respond to latanoprost therapy.Three hundred forty consecutive patients with a new diagnosis of POAG or OH, or previously treated only with a beta-blocker and after an appropriate washout period, were treated with latanoprost for 1 ...
Rossetti L +11 more
openaire +5 more sources
Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia
AAPS PharmSciTech, 2020Latanoprost has recently been used to treat alopecia as it causes an increase in the capillary density of patients. This work presents for the first time the development of polymeric nanocapsules containing latanoprost for the topical treatment of ...
Ana Christina S Oliveira +4 more
semanticscholar +1 more source
Effect of Latanoprost on Choroidal Thickness
Journal of Glaucoma, 2018Purpose:The purpose of this study was to evaluate the changes in choroidal thickness during the use of latanoprost eyedrops which shift fluid to the suprachoroidal space and change choroidal perfusion.Materials and Methods:This prospective study included 34 eyes of 17 bilateral glaucoma or ocular hypertensive patients who had no previous hypotensive ...
Nedime Sahinoglu-Keskek, Handan Canan
openaire +3 more sources
Latanoprost in hypotensive therapy of glaucoma
Vestnik oftal'mologii, 2018The review presents an analysis of therapeutic effectiveness, safety and pharmacokinetics of latanoprost - the reference representative of the prostaglandin group, summarizes the experience of its clinical use in glaucoma as monotherapy and in combination with antihypertensive drugs of other pharmacological groups, its possible effect on the ...
V P Erichev, V S Zinina
openaire +3 more sources